Article

Private equity and ophthalmology: Will I be left behind?

Conferences|GLAUCOMA 360

If you find yourself waffling back and forth on private equity, Ruth D. Williams, MD, has some guidance tips to make the decision easier. 

Ruth D. Williams, MD, shares the take-home message from her presentation, "Private Equity and Ophthalmology: Will I Be Left Behind?" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
Related Content
Cynthia Steel, PhD, MBA, appointed as Chief Scientific Officer of The Glaucoma Research Foundation
August 14th 2025

Cynthia Steel, PhD, MBA, appointed as Chief Scientific Officer of The Glaucoma Research Foundation

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
August 14th 2025

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Active lifestyle is tied to reduced visual field decline in primary open angle glaucoma
August 14th 2025

Active lifestyle is tied to reduced visual field decline in primary open angle glaucoma

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
August 14th 2025

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program
August 14th 2025

Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program

Kowa initiates phase 3 safety trial of NCX 470 in Japan
August 14th 2025

Kowa initiates phase 3 safety trial of NCX 470 in Japan

© 2025 MJH Life Sciences

All rights reserved.